Results 11 to 20 of about 87,437 (368)

The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia [PDF]

, 2013
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis.
A Blair, A Cesano, A Vilas-Zornoza, AG Renner, Alessandro Rambaldi, Alessia Casolaro, Alice Pezzoni, B Löwenberg, B Valsasina, Barbara Valsasina, C McInnes, Clara Albanese, D Raspadori, E Di Bona, E Estey, E Radaelli, EM Lee, Enrico Pesenti, F Ravandi, FR Appelbaum, Francesco Bertolini, Francesco Marchesi, G Tsykunova, Gemma Texido, Gianni Cazzaniga, H Chang, I Beria, J Delgado, J Golay, J Suela, J Zuber, Josee Golay, JR Novontny, JW Rocco, K Strebhardt, M Bardini, Marco Losa, Martino Introna, MJ Walter, MR Baer, Nadia Amboldi, PA Greif, R Giavazzi, Rachele Alzani, Roberta Ceruti, S Gattenloehner, Sabrina Cribioli, Silvia Bungaro, T Berg, T Ikezoe, T Lapidot, TJ Ley, U Cucchi, Ursula Giussani, Veronica Patton, Z Li   +55 more
core   +8 more sources

Development and Evaluation of Cellulose Derivative and Pectin Based Swellable pH Responsive Hydrogel Network for Controlled Delivery of Cytarabine

Gels, 2023
In the present study, pH-sensitive, biodegradable, and biocompatible Na-CMC/pectin poly(methacrylic acid) hydrogels were synthesized using an aqueous free radical polymerization technique and encapsulated by cytarabine (anti-cancer drug).
N. Batool, R. M. Sarfraz, Asif Mahmood, Umaira Rehman, M. Zaman, Shehla Akbar, Diena M. Almasri, Heba A. Gad   +7 more
semanticscholar   +1 more source

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine [PDF]

Journal of Clinical Oncology, 2005
Jorge E Romaguera, Barbara Pro, Andre H Goy   +2 more
exaly   +2 more sources

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Blood Advances, 2022
Key Points Adding idasanutlin to cytarabine to treat R/R AML improved overall remission rate (CR+CRi+CRp) but not overall survival (138).
M. Konopleva, C. Röllig, J. Cavenagh, D. Deeren, L. Girshova, J. Krauter, G. Martinelli, P. Montesinos, J. Schäfer, O. Ottmann, M. Petrini, A. Pigneux, A. Rambaldi, C. Récher, R. Rodríguez-Veiga, D. Taussig, N. Vey, S. Yoon, M. Ott, S. Muehlbauer, Benjamin M. Beckermann, O. Catalani, M. Genevray, K. Mundt, C. Jamois, P. Fenaux, A. Wei   +26 more
semanticscholar   +1 more source

The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA

HemaSphere, 2022
Resistance to cytarabine is a key problem in the treatment of acute myeloid leukemia (AML). To understand the molecular biology of resistance to cytarabine, a viability-based chemosensitizer screen was utilized. We screened synthetic lethal targets using
Miriam Rehberger, Jonas A. Schäfer, Anna-Maria Krampitz, Anne Catherine Bretz, Lukas Jost, Torsten Haferlach, Thorsten Stiewe, Andreas Neubauer   +7 more
doaj   +1 more source

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia

Nature Communications, 2022
Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates.
Rebecca G. Anderson, L. Miller, S. Isom, J. Chou, K. Pladna, Nathaniel J. Schramm, L. Ellis, D. Howard, Rupali Bhave, M. Manuel, S. Dralle, S. Lyerly, B. Powell, T. Pardee   +13 more
semanticscholar   +1 more source

A biophysical approach of cytarabine anticancer drug insights into human serum albumin and checkpoint kinase 1

Results in Chemistry, 2023
The present studies used biophysical techniques to examine the binding interaction mechanism of cytarabine anticancer drugs with human serum albumin (HSA) and checkpoint kinase 1.
Manoharan Rupavarshini, Subramani Karthikeyan, Sundaramoorthy Anandh, Anitha Ramamoorthi, Suganya Ramakrishnamurthy, Ganesan Bharanidharan, Prakasarao Aruna, Rajendiran Mangaiyarkarasi, Shanmugavel Chinnathambi, Ganesh N. Pandian, Singaravelu Ganesan   +10 more
doaj   +1 more source

Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers

Cancers, 2021
Simple Summary In this review, the authors propose a crosswise examination of cytarabine-related issues ranging from the spectrum of clinical activity and severe toxicities, through updated cellular pharmacology and drug formulations, to the genetic ...
R. Di Francia, S. Crisci, A. De Monaco, C. Cafiero, A. Re, G. Iaccarino, R. De Filippi, F. Frigeri, G. Corazzelli, A. Micera, A. Pinto   +10 more
semanticscholar   +1 more source

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Blood Cancer Discovery, 2021
Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-
J. Zeidner, B. Vincent, A. Ivanova, D. Moore, K. McKinnon, Alec D. Wilkinson, Rupkatha Mukhopadhyay, F. Mazziotta, H. Knaus, M. Foster, Catherine C Coombs, K. Jamieson, H. V. van Deventer, Jonathan A. Webster, G. Prince, A. DeZern, B. Smith, M. Levis, Nathan D. Montgomery, L. Luznik, J. Serody, I. Gojo   +21 more
semanticscholar   +1 more source

Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

Journal of Internal Medicine, 2022
Treatment of newly diagnosed acute myeloid leukaemia (AML) is based on combination chemotherapy with cytarabine (ara‐C) and anthracyclines. Five‐year overall survival is below 30%, which has partly been attributed to cytarabine resistance.
M. Jädersten, I. Lilienthal, Nikolaos Tsesmetzis, Magda Lourda, S. Bengtzén, Anna Bohlin, Cornelia Arnroth, T. Erkers, B. Seashore-Ludlow, G. Giraud, G. S. Barkhordar, Sijia Tao, L. Fogelstrand, L. Saft, P. Östling, R. Schinazi, B. Kim, T. Schaller, G. Juliusson, Stefan Deneberg, S. Lehmann, G. Rassidakis, M. Höglund, J. Henter, N. Herold   +24 more
semanticscholar   +1 more source